These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22429474)

  • 1. Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy).
    Thim T; Maeng M; Lassen JF; Kaltoft A; Jensen LO; Ravkilde J; Thayssen P; Galatius S; Christiansen EH; Engstrøm T; Madsen M; Thuesen L; Tilsted HH
    BMC Cardiovasc Disord; 2012 Mar; 12():18. PubMed ID: 22429474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
    Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
    Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy.
    Thim T; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Hansen PR; Kelbaek H; Thayssen P; Ravkilde J; Madsen M; Sørensen HT; Thuesen L; Lassen JF
    Eur J Clin Invest; 2012 Oct; 42(10):1047-54. PubMed ID: 22624990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
    Rasmussen K; Maeng M; Kaltoft A; Thayssen P; Kelbaek H; Tilsted HH; Abildgaard U; Christiansen EH; Engstrøm T; Krusell LR; Ravkilde J; Hansen PR; Hansen KN; Abildstrøm SZ; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Madsen M; Johnsen SP; Jensen LO; Sørensen HT; Thuesen L; Lassen JF;
    Lancet; 2010 Mar; 375(9720):1090-9. PubMed ID: 20231034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: the SEZE trial.
    Chung WY; Kang J; Cho YS; Park HJ; Yang HM; Seo JB; Suh JW; Kim KI; Youn TJ; Kim SH; Chae IH; Zo JH; Kim MA; Choi DJ
    Chin Med J (Engl); 2012 Oct; 125(19):3373-81. PubMed ID: 23044291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
    Kufner S; Sorges J; Mehilli J; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Rheude T; Ibrahim T; Massberg S; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):784-792. PubMed ID: 27017366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
    Massberg S; Byrne RA; Kastrati A; Schulz S; Pache J; Hausleiter J; Ibrahim T; Fusaro M; Ott I; Schömig A; Laugwitz KL; Mehilli J;
    Circulation; 2011 Aug; 124(5):624-32. PubMed ID: 21768546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; van der Heijden LC; Kok MM; Danse PW; Schotborgh CE; Scholte M; de Man FHAF; Linssen GCM; von Birgelen C
    JAMA Cardiol; 2019 Jul; 4(7):659-669. PubMed ID: 31111862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
    Colleran R; Kufner S; Harada Y; Giacoppo D; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Schneider S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):367-374. PubMed ID: 27377301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.
    Maeng M; Tilsted HH; Jensen LO; Kaltoft A; Kelbæk H; Abildgaard U; Villadsen AB; Krusell LR; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Madsen M; Thayssen P; Sørensen HT; Thuesen L; Lassen JF
    JACC Cardiovasc Interv; 2012 Aug; 5(8):812-8. PubMed ID: 22917452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents.
    Kufner S; Ernst M; Cassese S; Joner M; Mayer K; Colleran R; Koppara T; Xhepa E; Koch T; Wiebe J; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
    J Am Coll Cardiol; 2020 Jul; 76(2):146-158. PubMed ID: 32646563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
    Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.